FARE - Food Allergy Research & Education Logo

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Study Purpose

The Primary objective is to demonstrate the efficacy of dupilumab treatment compared with placebo in pediatric patients with active eosinophilic esophagitis (EoE) based on histologic improvement meeting validated histologic criteria. The Secondary objectives are:

  • - To demonstrate the efficacy of dupilumab compared to placebo in pediatric patients with active EoE after 16 weeks of treatment as assessed by endoscopic visual measurements of disease activity using the Eosinophilic Esophagitis-Endoscopic Reference Score (EoE-EREFS) and histologic abnormalities as measured by the EoE Histology Scoring System (EoE-HSS) - To evaluate the safety, tolerability, and immunogenicity of dupilumab treatment for up to 16 weeks in pediatric patients with active EoE.
  • - To evaluate the effects of dupilumab on transcriptomic signatures associated with EoE and type 2 inflammation.
  • - To study the effects of dupilumab on the type 2 inflammation gene expression signature.
  • - To evaluate the concentration-time profile of functional dupilumab in serum in this population.
  • - To assess efficacy of long-term (up to 160 weeks) dupilumab treatment.
  • - To assess the impact of dupilumab treatment on changes in weight and growth during the extended active period and open-label extension period of the study.
  • - To assess safety, tolerability, and immunogenicity of long-term (up to 160 weeks) dupilumab treatment.
- To evaluate the impact of dupilumab treatment on EoE signs and symptoms

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 1 Year - 11 Years
Gender All
More Inclusion & Exclusion Criteria

Key

Inclusion Criteria:

1. A documented diagnosis of eosinophilic esophagitis (EoE) 2. Baseline endoscopic biopsies with a demonstration on central reading of intraepithelial eosinophilic infiltration. Key

Exclusion Criteria:

1. Body weight <5 kg or ≥60 kg at screening. 2. Other causes of esophageal eosinophilia. 3. Active Helicobacter pylori. 4. History of Crohn's disease, ulcerative colitis, celiac disease, or prior esophageal surgery. 5. Any esophageal stricture unable to be passed with a standard, diagnostic, upper endoscope or any critical esophageal stricture that requires dilation at screening. 6. Treatment with swallowed topical corticosteroids within 8 weeks prior to baseline standard of care endoscopy. 7. History of bleeding disorders or esophageal varices that, in the opinion of the investigator, would put the patient at undue risk for significant complications from an endoscopy procedure. 8. Active parasitic infection or suspected parasitic infection. 9. Known or suspected immunodeficiency disorder. Key Exclusion for Patients Re-Entering the Study (for Entry into Part C, as defined in protocol): 1. Patients who are ≥12 years old, weigh ≥40 kg (or minimum weight for which dupilumab is approved for EoE), and dupilumab is commercially available for the treatment of EoE in their country. 2. Patients who, during their previous participation in this clinical trial, developed an SAE and/or AE deemed related to dupilumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with dupilumab may present an unreasonable risk for the patient. 3. Patients who did not undergo endoscopy with biopsies at week 16 and/or week 52 or prior to receiving rescue treatment Note: If the endoscopy with biopsies could not occur due to COVID-19 restrictions and rescue treatment was needed to be initiated without delay, these patients will be eligible to participate in Part C. 4. Patients who became pregnant during their previous participation in this dupilumab clinical trial. 5. Patients who, during their previous participation in this trial, were prematurely withdrawn because of a protocol violation, poor compliance, or inability to complete required study assessments. NOTE: Other protocol defined inclusion/exclusion criteria apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04394351
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Regeneron Pharmaceuticals
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Clinical Trial Management
Principal Investigator Affiliation Regeneron Pharmaceuticals
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Canada, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Eosinophilic Esophagitis (EoE)
Additional Details

This is a 3-part study:

  • - Part A: Double-blind 16-week treatment period.
  • - Part B: 36-week extended active treatment period.
- Part C: Up to108 weeks open-label extension period

Arms & Interventions

Arms

Experimental: Part A - High Dose

Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

Experimental: Part A - Low Dose

Part A consists of a 16-week double-blind treatment period. Patients will be randomized to receive dupilumab or placebo subcutaneous (SC) administration at tiered dosing regimens based on body weight

Experimental: Part B - High Dose

Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

Experimental: Part B - Low Dose

Part B consists of a 36-week extended active treatment period. All patients to receive subcutaneous (SC) administration at tiered dosing regimens based on body weight

Experimental: Part C - High Dose

Part C consists of up to 108-week open-label extension period. All patients will receive higher exposure dupilumab subcutaneous (SC) administration at tiered dosing regimens based on body weight. No matching placebo administered in Part C.

Interventions

Drug: - Dupilumab

Single-use, prefilled syringe

Drug: - Matching Placebo

Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Regeneron Study Site, Phoenix, Arizona

Status

Address

Regeneron Study Site

Phoenix, Arizona, 85016

Regeneron Study Site, Little Rock, Arkansas

Status

Address

Regeneron Study Site

Little Rock, Arkansas, 72202

Regeneron Study Site, Los Angeles, California

Status

Address

Regeneron Study Site

Los Angeles, California, 90027

Regeneron Study Site, San Francisco, California

Status

Address

Regeneron Study Site

San Francisco, California, 94143

Regeneron Study Site, Aurora, Colorado

Status

Address

Regeneron Study Site

Aurora, Colorado, 80045

Regeneron Study Site, Saint Petersburg, Florida

Status

Address

Regeneron Study Site

Saint Petersburg, Florida, 33701

Regeneron Study Site, Atlanta, Georgia

Status

Address

Regeneron Study Site

Atlanta, Georgia, 30322

Regeneron Study Site, Atlanta, Georgia

Status

Address

Regeneron Study Site

Atlanta, Georgia, 30342

Regeneron Study Site, Chicago, Illinois

Status

Address

Regeneron Study Site

Chicago, Illinois, 60611

Regeneron Study Site, Indianapolis, Indiana

Status

Address

Regeneron Study Site

Indianapolis, Indiana, 46202

Regeneron Study Site, Iowa City, Iowa

Status

Address

Regeneron Study Site

Iowa City, Iowa, 52242

Regeneron Study Site, Boston, Massachusetts

Status

Address

Regeneron Study Site

Boston, Massachusetts, 02111

Regeneron Study Site, Boston, Massachusetts

Status

Address

Regeneron Study Site

Boston, Massachusetts, 02114

Regeneron Study Site, Boston, Massachusetts

Status

Address

Regeneron Study Site

Boston, Massachusetts, 02115

Regeneron Study Site, Lincoln, Nebraska

Status

Address

Regeneron Study Site

Lincoln, Nebraska, 68510

Regeneron Study Site, New York, New York

Status

Address

Regeneron Study Site

New York, New York, 10029

Regeneron Study Site, New York, New York

Status

Address

Regeneron Study Site

New York, New York, 10032

Regeneron Study Site, New York, New York

Status

Address

Regeneron Study Site

New York, New York, 10065

Regeneron Study Site, Chapel Hill, North Carolina

Status

Address

Regeneron Study Site

Chapel Hill, North Carolina, 27599

Regeneron Study Site, Cincinnati, Ohio

Status

Address

Regeneron Study Site

Cincinnati, Ohio, 45229

Regeneron Study Site, Cleveland, Ohio

Status

Address

Regeneron Study Site

Cleveland, Ohio, 44106

Regeneron Study Site, Philadelphia, Pennsylvania

Status

Address

Regeneron Study Site

Philadelphia, Pennsylvania, 19104

Regeneron Study Site, Dallas, Texas

Status

Address

Regeneron Study Site

Dallas, Texas, 75207

Regeneron Study Site, Fort Worth, Texas

Status

Address

Regeneron Study Site

Fort Worth, Texas, 76104

Regeneron Study Site, Houston, Texas

Status

Address

Regeneron Study Site

Houston, Texas, 77030

Regeneron Study Site, Milwaukee, Wisconsin

Status

Address

Regeneron Study Site

Milwaukee, Wisconsin, 53226

International Sites

Regeneron Study Site, London, Ontario, Canada

Status

Address

Regeneron Study Site

London, Ontario, N6A 5W9

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.